<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385161</url>
  </required_header>
  <id_info>
    <org_study_id>61352</org_study_id>
    <nct_id>NCT03385161</nct_id>
  </id_info>
  <brief_title>Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia</brief_title>
  <official_title>Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia Refractory to Medical Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safely and efficacy of intraprostatic injection of botulinum toxin A versus
      ethanol for treatment of benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare safely and efficacy of transrectal intraprostatic injection of botulinum toxin A
      versus ethanol for treatment of symptomatic benign prostatic hyperplasia (BPH) refractory to
      medical treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the surgeon during injection knows the active material</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>International prostate symptom score (IPSS)</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>7 items Questionnaire with a score range from 0 - 35 (5 points for each item) A score of 35 is considered the worst The score is calculated during each period of follow-up The difference in the score in each group will be compared versus each other to detect any significant difference between both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate (Qmax)</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>The peak flow rate measured during flowmetry (mL/Sec) Increase in the flow rate is considered improvement The Qmax is calculated during each period of follow-up by flowmetry The difference in the Qmax in each group will be compared versus each other to detect any significant difference between both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>Prostate volume (PV) will be measured by transrectal US (Cubic cm) Decrease in size is considered improvement The PV is calculated during each period of follow-up The difference in the PV in each group will be compared versus each other to detect any significant difference between both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QoL)</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>one items Questionnaire It is the QoL portion of the International prostate symptom score (IPSS) The score range from 0 - 6 A score of 6 is considered the worst The score is calculated during each period of follow-up The difference in the score in each group will be compared versus each other to detect any significant difference between both groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>retention of urine</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>Significant difference between the rate (%) of development of retention of urine in both groups during follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Other lines of treatment including TURP</measure>
    <time_frame>1, 3, 6 months and one year</time_frame>
    <description>Significant difference between the rate (%) of required TURP and other lines of treatment in both groups (due to failure of studied intervention to improve symptoms of the patient )</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Male</condition>
  <condition>Ultrasonography</condition>
  <condition>Botulinum Toxins, Type A</condition>
  <condition>Injection; Complications, Infection</condition>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.
One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.
one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.
An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.
one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <other_name>onaBONT/A</other_name>
    <other_name>botox</other_name>
    <other_name>onabotulinumtoxinA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <arm_group_label>Ethanol</arm_group_label>
    <other_name>dehydrated ethanol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  international prostate symptoms score (IPSS) &gt; 7

          -  Qmax &lt; 15

          -  Patients with refractory symptomatic BPH to medications

          -  patients high risk for surgery or unwilling to do surgery

        Exclusion Criteria:

          -  bladder stones

          -  acute or chronic urinary retention

          -  urethral stricture

          -  bladder or prostatic carcinoma.

          -  Neurogenic bladder dysfunctions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate is only in males</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed S ElSheemy, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>12222</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Totaro A, Pinto F, Pugliese D, Vittori M, Racioppi M, Foschi N, Bassi PF, Sacco E. Intraprostatic botulinum toxin type &quot;A&quot; injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation. Neurourol Urodyn. 2018 Mar;37(3):1031-1038. doi: 10.1002/nau.23390. Epub 2017 Aug 25.</citation>
    <PMID>28840969</PMID>
  </results_reference>
  <results_reference>
    <citation>Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, Zhou J, Patel A, Haag-Molkenteller C. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013 Mar;63(3):496-503. doi: 10.1016/j.eururo.2012.10.005. Epub 2012 Oct 12.</citation>
    <PMID>23098762</PMID>
  </results_reference>
  <results_reference>
    <citation>Magno C, Mucciardi G, Gal√¨ A, Anastasi G, Inferrera A, Morgia G. Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients. Int Urol Nephrol. 2008;40(4):941-6. doi: 10.1007/s11255-008-9394-z. Epub 2008 May 14.</citation>
    <PMID>18478352</PMID>
  </results_reference>
  <results_reference>
    <citation>Sakr M, Eid A, Shoukry M, Fayed A. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up. Int J Urol. 2009 Feb;16(2):196-201. doi: 10.1111/j.1442-2042.2008.02205.x. Epub 2008 Nov 27.</citation>
    <PMID>19054163</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mohammed Said ElSheemy</investigator_full_name>
    <investigator_title>Associate Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>ethanol ablation of the prostate</keyword>
  <keyword>Benign prostatic hyperplasia (BPH)</keyword>
  <keyword>Prostate</keyword>
  <keyword>Ethanol</keyword>
  <keyword>Transrectal</keyword>
  <keyword>BPH</keyword>
  <keyword>onaBoNT-A</keyword>
  <keyword>Botox</keyword>
  <keyword>Lower urinary tract symptoms</keyword>
  <keyword>Botulinum toxin</keyword>
  <keyword>OnabotulinumtoxinA</keyword>
  <keyword>Quality of life</keyword>
  <keyword>IPSS</keyword>
  <keyword>Randomised controlled study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

